Literature DB >> 3203058

Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies.

G R Loewen1, R J Herman, S G Ross, R K Verbeeck.   

Abstract

1. The effect of dose (100 mg, 250 mg, 500 mg, 750 mg and 1000 mg) on the glucuronidation and sulphation of diflunisal was studied in six healthy volunteers. 2. Total urinary recovery ranged from 78.9 +/- 11.9% to 91.5 +/- 18.7% of the administered dose. Urinary recovery (normalized for total urinary recovery) of diflunisal sulphate (DS) significantly increased with dose from 9.3 +/- 3.7% to 18.1 +/- 4.8%. 3. Normalized urinary recovery for diflunisal phenolic glucuronide (DPG) was unaffected by dose (range: 30.6 +/- 3.8% to 40.6 +/- 6.6%). Normalized urinary recovery for the acyl glucuronide (DAG) significantly decreased from 52.3 +/- 4.6% to 40.2 +/- 3.4% as the dose increased. 4. Total plasma clearance of diflunisal significantly decreased from 14.4 +/- 1.4 ml min-1 to 8.7 +/- 1.4 ml min-1 as the dose increased from 100 mg to 750 mg. A further increase in dose to 1000 mg resulted in an unexplained increase in total plasma clearance to 10.3 +/- 1.8 ml min-1. 5. Dose-dependent plasma clearance of diflunisal was caused mainly by saturation of the formation of DAG, whereas the formation of DS and DPG were relatively unaffected by dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203058      PMCID: PMC1386496          DOI: 10.1111/j.1365-2125.1988.tb03360.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Diflunisal: a review of pharmacokinetic and pharmacodynamic properties, drug interactions, and special tolerability studies in humans.

Authors:  K F Tempero; V J Cirillo; S L Steelman
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

Review 2.  Pharmacokinetic consequences and toxicologic implications of endogenous cosubstrate depletion.

Authors:  G Levy; R E Galinsky; J H Lin
Journal:  Drug Metab Rev       Date:  1982       Impact factor: 4.518

Review 3.  Drug metabolite kinetics.

Authors:  J B Houston
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

4.  Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency.

Authors:  R Verbeeck; T B Tjandramaga; A Mullie; R Verbesselt; R Verberckmoes; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

5.  Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic.

Authors:  R K Verbeeck; A Boel; A Buntinx; P J De Schepper
Journal:  Biochem Pharmacol       Date:  1980-02-15       Impact factor: 5.858

6.  Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.

Authors:  R A Upton; J N Buskin; R L Williams; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

7.  Pharmacokinetics of salicylamide elimination in man.

Authors:  G Levy; T Matsuzawa
Journal:  J Pharmacol Exp Ther       Date:  1967-05       Impact factor: 4.030

8.  Isolation and identification of a new major metabolite of diflunisal in man. The sulfate conjugate.

Authors:  G R Loewen; G McKay; R K Verbeeck
Journal:  Drug Metab Dispos       Date:  1986 Jan-Feb       Impact factor: 3.922

Review 9.  Diflunisal: a review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis.

Authors:  R N Brogden; R C Heel; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-02       Impact factor: 9.546

10.  Salicylate clearance, the resultant of protein binding and metabolism.

Authors:  D E Furst; T N Tozer; K L Melmon
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

View more
  8 in total

1.  Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.

Authors:  J I Macdonald; S M Wallace; V Mahachai; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

3.  The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.

Authors:  R K Verbeeck; G R Loewen; J I MacDonald; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

4.  Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisal.

Authors:  R G Dickinson; A R King; G E McKinnon; W D Hooper; M J Eadie; G K Herkes
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

5.  Diflunisal and its conjugates in patients with renal failure.

Authors:  R G Dickinson; R K Verbeeck; A R King; A C Restifo; S M Pond
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

6.  Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal.

Authors:  J I Macdonald; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 7.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

8.  Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal.

Authors:  J I Macdonald; S M Wallace; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.